Erschienen in:
01.11.2012 | Original Article
Impact of oxaliplatin-induced neuropathy: a patient perspective
verfasst von:
Barbara K. Bennett, Susanna B. Park, Cindy S.-Y. Lin, Michael L. Friedlander, Matthew C. Kiernan, David Goldstein
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 11/2012
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Dose-limiting neurotoxicity is a major side effect of oxaliplatin treatment, producing initial acute neurotoxicity and chronic neuropathy with increasing exposure. The improvement in survival for patients with early-stage colorectal cancer treated with oxaliplatin has highlighted the need for valid and reliable assessment of peripheral neuropathy.
Objectives
The objective of this paper was to explore neuropathic symptoms in oxaliplatin-treated patients as assessed using different methods.
Methods
Consecutive symptomatic patients reporting peripheral neuropathy after oxaliplatin chemotherapy for colorectal cancer were interviewed using a semi-structured clinical interview. Neurotoxicity was also assessed using the National Cancer Institute Common Toxicity Criteria scale (clinician-rated), patient ‘self-report’ questionnaires (PNQ), nerve conduction and clinical assessment.
Results
Twenty patients were assessed, 12.6 ± 2.8 months after treatment cessation (mean cumulative oxaliplatin dose, 789 mg/m2). In 40% of patients, neurotoxicity necessitated early cessation of treatment. Only 10% of patients were designated by clinicians with severe neurotoxicity, whilst, in contrast, patient interviews and self-report questionnaires described significant physical limitations due to neuropathic symptoms in 60% of patients. The majority (85%) of patients had objective evidence of sensory neuropathy with nerve conduction studies. Reports from clinical interviews were strongly correlated with patient self-assessment (Pearson coefficient = 0.790, p < 0.0005).
Conclusion
Given the discrepancies in symptom prevalence highlighted by these findings, the monitoring of oxaliplatin-induced neurotoxicity would benefit from more informative clinical assessment, with inclusion of patient-reported outcome measures. Such an approach would be beneficial in a clinical trial setting to monitor the efficacy of interventions and in prospective studies of survivorship to determine the true burden of peripheral neuropathy in oxaliplatin-treated patients.